Skip to content
DataLookout
Menu

NCT04459065

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
  2. Notable Primary completion date: Sep 2023 to Sep 2026
    • Study completion date: Mar 2024 to Oct 2026
    v5
  3. Notable Primary completion date: Sep 2022 to Sep 2023
    • Study completion date: Sep 2022 to Mar 2024
    v4
  4. Minor Start date changed from estimate of Sep 2020 to Sep 1, 2020v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 2022 to Sep 2022
    • Start date: Aug 2020 to Sep 2020
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1: Optimal dose of IRDye800CW-nimotuzumab for image guided surgery.
Timeframe: up to 14 days
Phase 2: Determine the optimal time for IRDye800CW-nimotuzumab infusion for image guided surgery.
Timeframe: up to 14 days

Secondary (3)

Determine primary tumor margins.
Identify EGFR positive lymph nodes.
Safety of IRDye800CW-nimotuzumab

Arms and interventions

Low dose intermediate timeExperimental

Participants will receive an i.v. infusion of 50 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration

High dose intermediate timeExperimental

Participants will receive an i.v. infusion of 100 mg IRDye800CW-nimotuzumab. Participants will undergo lung cancer resection surgery 4-6 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration

Optimal dose early timeExperimental

Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on results from cohorts 1 and 2). Participants will undergo lung cancer resection surgery 1-3 days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration

Optimal dose late timeExperimental

Participants will receive an i.v. infusion of 50 or 100 mg IRDye800CW-nimotuzumab (depending on cohorts 1 and 2). Participants will undergo lung cancer resection surgery 7+ days after infusion. Vitals, blood sample and urine sample will be collected before infusion for a baseline. Blood and vitals will be taken post infusion. Blood and urine samples will be collected on the day of surgery. Participants will be followed up for any adverse event until day 30 post administration

Drugs: IRDye800CW-nimotuzumab

Sites

1 site in 1 country

  • St. Paul's HospitalSaskatoon, Saskatchewan, Canada